Protective role of ceftriaxone plus sulbactam with VRP1034 on oxidative stress, hematological and enzymatic parameters in cadmium toxicity induced rat model

Vivek Kumar DWIVEDI 1, Anuj BHATANAGAR 2, Manu CHAUDHARY 1
1 Preclinical Division, Venus Medicine Research Centre, Baddi, H.P. 173205 India
2 Analytical Division, Venus Medicine Research Centre, Baddi, H.P. 173205 India

ABSTRACT
We investigated the protective role of ceftriaxone plus sulbactam with VRP1034 on hematological, lipid peroxidation, antioxidant enzymatic activities and Cd levels in the blood and tissues of cadmium exposed rats. Twenty-four male rats were divided into three groups of eight rats each. The control group received distilled water whereas group II received CdCl₂ (1.5 mg/4 ml/body weight) through gastric gavage for 21 days. Group III received CdCl₂ and was treated with ceftriaxone plus sulbactam with VRP1034 for 21 days. The hematological, biochemical, lipid per-oxidation levels and enzymatic parameters were measured in plasma and tissues (brain, liver and kidney) of all groups. The Cd, Zn and Fe levels were measured in blood and tissues of all groups. Our findings showed significantly decreased cadmium (p<0.001), malonaldehyde (p<0.001) and myloperoxidase (MPO) levels along with significantly increased hemoglobin (p<0.01), RBC (p<0.05), hematocrit (p<0.05) levels and all antioxidant enzymatic activities (SOD, CAT, GR, Gpx) in plasma and tissues of ceftriaxone plus sulbactam with VRP1034 treated group as compared to cadmium exposed group. Delta aminolevulinate dehydratase (δ-ALAD) activity was significantly (p<0.001) increased in the blood of ceftriaxone plus sulbactam with VRP1034 treated group as compared with cadmium exposed group. The levels of hepatic and renal parameters were significantly (p<0.001) decreased in ceftriaxone plus sulbactam with VRP1034 treated group as compared to cadmium exposed group. These findings indicate that ceftriaxone plus sulbactam with VRP1034 acts as a potent free radical scavenger and exhibits metal chelating properties that reduce free radical mediated tissue injury and prevent dysfunction of hepatic and renal organs during metal intoxication.

KEY WORDS: cadmium toxicity; hematological and biochemical parameters; oxidative stress and enzymatic parameters; hepatic and renal tissues; Elores

LIST OF ABBREVIATIONS
SOD: superoxide dismutase; CAT: catalase; GR: glutathione reductase; Gpx: glutathione peroxidase; GST: Glutathione S-transferase; MDA: malonaldehyde; GSH: reduced glutathione; GSSG: Oxidized glutathione; MPO: myloperoxidase; FDC: fixed dose combination
XO: Xanthine oxidase

Introduction
Cadmium (Cd) is an industrial and environmental pollutant, arising primarily from batteries, electroplating, pigment, plastic, fertilizer industries, and cigarette smoke. It is dangerous because humans consume both plants and animals that absorb Cd efficiently and concentrate it within their tissues (Stohs & Bagchi, 1995). Cd operates by various mechanisms of toxicity in particular species and under different experimental conditions (Iscan et al., 1994; Žikić et al., 1996; Waisberg et al., 2003). Cd was found to stimulate free radical production, resulting in oxidative deterioration of lipids, proteins and DNA, and initiating various pathological conditions in humans and animals (Waisberg et al., 2003). Chronic exposure to inorganic Cd results in accumulation of the metal mainly in the liver and kidneys, as well as in other tissues and
organs, causing many metabolic and histological changes, membrane damage, altered gene expression and apoptosis (Waisberg et al., 2003; Shaikh et al., 1999; Casalino et al., 2002a). A number of cadmium-induced effects include deterioration of cell to cell adhesion, DNA-related processes cell signaling and energy metabolism, implying that this metal acts on different molecular targets in human organs. Cadmium was shown to induce apoptosis in mouse liver (Michael et al., 1999).

Ceftriaxone plus sulbactam with VRP1034 is a novel fixed dose combination drug. Ceftriaxone is the third generation the cephalosporin class of antibiotics, whereas sulbactam is a β-lactamase inhibitor. It is well established that cephalosporins act as multidentate chelating agents (Anacona & Rodríguez, 2005; Anacona & Osorio, 2008). Besides this property, cephalosporins are known as a thioether containing class of antibiotics, which are rather effective in preventing free radical-mediated oxidation of sulfhydryl groups in the antibiotics. Various studies reported that ceftriaxone and sulbactam individually showed free radical scavenging property (Lapenna et al., 1995; Gunther et al, 1993). It is well known that sulbactam acts as oxidant scavenger and inhibits in vitro neutrophil function (Santos and Arbo, 1989). VRP1034 is a third vector between these two drugs. VRP1034 has chelating and free radical scavenger properties. VRP1034 is a patent protected trade secrete. It has already been reported that a novel fixed dose combination of ceftriaxone plus sulbactam with VRP1034 play also a significant role in various bacterial infections (Dwivedi et al., 2010). The aim of this study was to investigate the protective effect of ceftriaxone plus sulbactam with VRP1034 on hematological, biochemical and some enzymatic parameters in blood and tissues of cadmium exposed rats.

Material and methods

Chemicals

All biochemicals used in the present study were procured from Sigma, St. Louis, MO, USA. δ-aminolevulinic acid (δ-ALA) and cadmium chloride were purchased from Sigma Chemical, St Louis, MO, USA. Other chemicals purchased locally, were of analytical grade. Ketamine hydrochloride was purchased from Samarth Life Science Pvt. Ltd. Mumbai. Other biochemical kits were procured from Erba Diagnostics Mannheim Gmb, Germany.

Drugs

Ceftriaxone plus sulbactam with VRP1034 was obtained from Venus Remedies Ltd., Baddi, H.P. The ratio of ceftriaxone plus sulbactam to VRP1034 was 2:1 respectively.

Animals

The animals were obtained from the animal house facility of Venus Medicine Research Centre, Baddi, H.P. The experiment was carried out after approval from the Institutional Animal Ethics Committee (IAEC). The IAEC number for this study was IAEC/CSV/2011-05.

The study was performed on male wistar rats weighing 140±10 g, housed in polypropylene cages in an air-conditioned room with temperature maintained at 25±2°C and 12 h alternating day and night cycles. The animals were allowed standard rat chow diet and sterile distilled water.

Experimental design

Twenty four male rats were selected and divided into three groups of eight rat each:

- Group I: Control normal saline treated group
- Group II: CdCl2 induced group (1.5mg /4ml /kg body weight)
- Group III:CdCl2+Ceftriaxone plus sulbactam with VRP1034 treated group (155.0 mg/kg body weight/day)

Cadmium chloride (CdCl2) was given to sixteen animals through gastric gavage daily for 21 days and eight animals received plane distilled water and served as control. Toxicity was confirmed after showing signs such as loss of appetite, body weight loss, decreased hemoglobin and increased body temperature. After confirmation of toxicity, drug was given only to group III animals through intravenous route for 21 days and body weight, body temperature, food and water intake along with hematological parameters were recorded. All the animals were decapitated 24 hour after last treatment, 2.5 ml blood was collected in EDTA containing vials and liver, kidney and brain tissues were collected in chilled phosphate buffer saline and washed three times with chilled PBS and homogenates were prepared for measurement of biochemical and enzymatic parameters.

Plasma preparation

A sample of 1.5 ml blood was centrifuged at 6000 rpm for 15 minutes and the supernatant was carefully taken into a polypropylene tube and stored at 2–8°C for measurement of antioxidant enzymatic and biochemical parameters. The remaining part of blood samples was used for determination of metal and δ-aminolevulinic acid dehydratase activity.

Homogenate preparation

Liver, brain and kidney tissue homogenates (10%) were prepared in chilled phosphate buffer-NaCl solution containing 0.15 mol/L NaCl in 0.05 mol/L, Na2HPO4-NaH2PO4 buffer (pH7.2) and left for at least 1 hr at 2–8°C before measurement of enzymatic and biochemical parameters.

Determination of hematological parameters

Hematological parameters were tested with automatic cell counter (Sysmex XT 2000i).

Blood δ-aminolevulinic acid dehydratase (ALAD) activity

ALAD activity was assayed in the blood according to the method of Berlin and Schaller (1974). For measurement of δ-ALAD activity, 0.2ml of blood was taken and mixed with 1.3ml double distilled water and the test tubes were incubated for 10 minutes at 37°C for complete hemolysis.
After incubation of all test tubes, 1.0 ml of δ-ALA standard solution was added and further all test tubes were incubated for one hr at 37°C. The reaction was stopped after one hr by adding 1.0 ml of 10% TCA solution. All test tubes were centrifuged at 600 g for 5 to 10 min. After centrifugation, 1.5 ml of supernatant was taken in clean test tubes and equal amount of Ehrlich reagent was added and absorbance was recorded at 555 nm wavelength after 5 min. The molar extinction coefficient 6.1 × 10^4 was used for calculation.

**Enzymatic parameters**

All enzymatic parameters were standardized at 25°C

**Superoxide dismutase assay (SOD; EC 1.15.1.1)**

SOD activity was determined in plasma and tissues by the Method of Misra and Fridovich (1972). The reaction mixture consisted of 1.0 ml carbonate buffer (0.2 M, pH 10.2), 0.8 ml KCl (0.015M), 0.1 ml of plasma and tissue mixture consisted of 1.0 ml carbonate buffer (0.2 M, 2 mM NAPDH, 0.2 ml of 20 mM oxidized glutathione), 20 μl of sample and 2.53 ml distilled water was added. The reaction was started by adding 0.2 ml of epinephrine (0.025M). The change in absorbance was recorded at 480 nm at 15 second intervals for one minute at 25°C. Suitable control lacking enzyme preparation was run simultaneously.

One unit of enzyme activity is defined as the amount of enzyme causing 50% inhibition of auto-oxidation of epinephrine.

**Catalase assay (CAT; EC 1.11.1.6)**

Catalase activity was measured in plasma and tissues according to the procedure of Aebi (1984) at room temperature with slight modification. Plasma (100 μl) and 0.025 of ml tissues were added in clean tubes and kept on ice bath for 30 minutes at room temperature. Triton-X (10 μl) was added to each plasma and tissue containing test tube. In a cuvette, to 200 μl phosphate buffer (0.2 M; pH 6.8), 20 μl of sample and 2.53 ml distilled water was added. The reaction was started by adding 250 μl of H2O2 (0.066 M in phosphate buffer) and decrease in optical density was recorded at 240 nm wavelength every 15 second for one minute. The molar extinction coefficient of 43.6 M Cm⁻¹ was used for determination of catalase activity.

One Unit of enzyme activity was defined as the amount of enzyme that liberates half of the peroxide oxygen from H2O2 in one minute at 25°C.

**Glutathione reductase activity (GR; EC 1.6.4.2)**

GR activity was measured in plasma and tissues by the method of Carlberg and Mannervik (1985). The reaction mixture consisted of 1.5 ml potassium phosphate buffer (0.2 M, pH 7.0) containing 2 mM EDTA, 0.15 ml of 2 mM NADPH, 0.2 ml of 20 mM oxidized glutathione and distilled water to make up the final volume of 3.0ml. The reaction was started by adding 0.1 ml of plasma homogenate in the linearity range. The absorbance was measured at 340 nm for one minute at 15 sec. intervals. Control lacking enzyme was run simultaneously.

One unit of GR activity is expressed as the amount of NADP formed in one minute by one ml of enzyme preparation. Calculation of the enzyme activity was done by using the molar extinction coefficient of NADPH as 6.22 × 10³.

**Glutathione peroxidase activity (GPx; EC 1.11.1.9)**

GPx activity was measured by the method described by Rotruck et al., (1973). The reaction mixture contained 0.2 ml of 0.4 M Tris-HCl buffer pH 7.0, 0.1 ml of 10 mM sodium azide, 0.2 ml of homogenate, 0.2 ml glutathione, 0.1 ml of 0.2 mM H2O2. The contents were incubated at 37°C for 10 min. The reaction was arrested by 0.4 ml of 10% TCA and centrifuged. The supernatant was assayed for glutathione content by using Ellmans reagent (19.8 mg of 5,5'-dithiobisnitro benzoic acid (DTNB) in 100 ml of 0.1% sodium nitrate).

**Glutathione S-transferase activity (GST; EC 2.5.1.18) activity**

Glutathione S-transferase activity in plasma and tissue spectrophotometry at 480 nm and 37°C was followed by conjugation of the acceptor substrate1-chloro-2,4-dinitrobenzen as described by Herbig et al. (1974). The absorbance was calculated from the extinction coefficient 9.6 mM/Cm.

**Reduced glutathione (GSH) measurement**

Reduced glutathione was assayed by the method of Ellman (1959). Samples of 0.5 ml plasma and 0.25 ml tissue were mixed with equal amount of 5% (w/v) TCA reagent and kept for 10 min at room temperature, proteins were precipitated and the filtrate was removed carefully after centrifugation at 3500 rpm for 15 minutes. Filtrate (0.25 ml) was taken and added to 2.0 ml of Na2HPO4 (4.25%)and 0.04 ml of DTNB (0.04%). A blank sample was prepared in similar manner using double distilled water instead of the filtrate. A pale yellow color was developed and optical density was measured at 412 nm by a spectrophotometer.

**Total thiol determination**

Total thiol content was analyzed by the method of Hu (1994). Plasma and tissue samples (0.2 ml) were taken in test tubes and 0.6 ml of Tris EDTA buffer (Tris 0.25M; EDTA 20mM; pH 8.2) was added, followed by 40μl of 10mM of 5,5’ dithionitrobi 2-nitrobenzoic acid (DTNB in methanol) and the total reaction volume of 4.0 ml was obtained by adding 3.16 ml of methanol. All test tubes were sealed and the color was developed for 15–20 min, followed by centrifugation at 3000 g for 10–15 min at room temperature. The absorbance of the supernatant was measured at 412 nm wavelength.

**Xanthine oxidase (XO; EC 1.17.3.2) activity**

XO (Xanthine oxidase) was assayed in plasma and homogenate by the method of Fried and Fried (1945). The reaction mixture consisted of 0.9 ml of 0.1 M phosphate buffer pH 7.8; 0.75 ml 10 mM EDTA; 0.15 ml 0.2 mg/ml phenazine methosulphate; 0.45 ml 4 mg/ml nitroblue tetrazolium (NBT) salt; 0.5 ml; 1 mM xanthine and water to reach the volume of 3.5 ml. The reaction was started at 37°C by addition of 0.5 ml of 1 mM Xanthine for 1 min.
Extinction coefficient of the reduced NBT at 540 nm is 7.2 cm/μmole. One unit of enzyme activity was defined as the amount of enzyme that converted 1 μ mole of xanthine to uric acid in one minute at specified assay conditions.

Measurement of myeloperoxidase (MPO; EC 1.11.2.2)
Myeloperoxidase was determined by O-dianisidine method with slight modification Kurutas et al., (2005). The assay mixture consisted of 0.3 ml of sodium phosphate buffer (0.1 M; pH 6.0), 0.3 mL of H2O2 (0.01 M), 0.2 mL of O-dianisidine (0.02 M) (freshly prepared in distilled water) and final volume of 3.0 ml was obtained with distilled water. The reaction was started by addition of 0.025 ml samples. The change in absorbance was recorded at 460 nm wavelength. All measurements were carried out in duplicate. One unit of enzyme activity was defined as the increase in absorbance of 0.001 min⁻¹.

Measurement of lipid peroxidation level
Free radical mediated damage was assessed by the measurement of lipid peroxidation in the term of malondialdehyde (MDA) formed, essentially according to method of Ohkawa et al., (1979). It was determined by thio barbituric reaction. The reaction mixture consisted of 0.2 ml samples, 0.20 ml of 8.1% sodium dodecyl sulphate (SDS), 1.5 ml of (20%, pH 3.5) acetic acid, 1.5 ml of 0.8% thio barbituric acid (TBA) and 0.6 ml distilled water to see find volume of 4.0 ml. The tubes were kept in boiled water at 95°C for one hr and cooled immediately under running tap water. The amount of 1.0 ml of water was added to and 5.0 ml of the mixture of n-butanol and pyridine (15:1 v/v) and vortexed. The tubes were centrifuged at 3500 rpm for 15–20 minutes. The upper layer was aspirated and optical density was measured at 532 nm. The molar extension coefficient 1.56x 10⁵ was used for calculation.

Determination of biochemical parameters
The total protein, hepatic and renal enzymes (SGOT, SGPT, Creatinine and ALP levels) were measured in the plasma sample by standard kit method.

Metal determination
For assessment of cadmium, iron and zinc concentration in blood and tissues, 0.5 ml samples (blood, liver, kidney and brain) were mixed with 4.5 ml of acidic glycerol (1% HNO₃ and 5% glycerol mixture) and the final volume of 10.0 ml was obtained with distilled water. Cadmium, iron and zinc were measured by using a flame atomic absorption spectrophotometer (Analytikjena, model No. contra A300, Germany) with hollow-cathode lamp at wave length 228.8 nm (Cd), 248.0 nm (Fe) and 213.9 nm (Zn). The direct absorption of the solution was determined by the atomic absorption spectrophotometer and suitable standard curves of each metal were prepared by using 20 to 100 µg/ml. All chemicals used for metal measurements were of Merck reagent grade.

Statistical analysis
All values were expressed as Mean ± SD. One-way analysis of variance (ANOVA) followed by Newman-Keuls comparison test was used to determine statistical difference between control vs cadmium exposed group and cadmium exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group. The p-values <0.05 were considered statistically significant.

Results
SOD and CAT enzyme activities were significantly decreased (p<0.001) in plasma, (p<0.001) in brain, (p<0.001; p<0.01), in liver (p<0.001) and (p<0.001; p<0.01) in kidney tissues of Cd exposed group as compared to control group. After treatment with ceftriaxone plus sulbactam with VRP1034 for three weeks, these enzyme activities were significantly increased (p<0.01; p<0.05) in plasma and (p<0.001) in brain tissues of the treated
group as compared to the Cd exposed group. In liver and kidney tissues only SOD activity was increased significantly \((p<0.001)\), while catalase activity was found to be insignificantly increased \((p>0.05)\) in the treated group as compared to the cadmium exposed group after 21 days treatment (Figures 1 and 2). The cadmium chloride exposed group showed a significant reduction \((p<0.001)\) of glutathione reductase activity in plasma, brain and renal tissue as compared to the control group, while this enzyme was found insignificantly \((p>0.05)\) decrease in liver tissue in comparison with the control group. After treatment with the drug for 21 days, this enzyme activity was significantly increased only in plasma while in all tissue homogenates this enzyme activity appeared insignificantly increased \((p>0.05)\) in treated group as compared with the cadmium exposed group (Figure 3). GPX activity was significantly \((p<0.001)\) decreased in plasma, hepatic and renal tissues of the cadmium exposed group as compared to the control group, while in the brain the enzyme activity was reduced insignificantly \((p>0.05)\) as compared to the control group. After treatment with C+S with VRP1034 through intravenous route for 21 days, the enzyme activity was significantly elevated \((p<0.001)\) in the liver and \((p>0.05)\) in renal tissue while the activity was found insignificantly \((p>0.05)\) increased in plasma and brain tissue of the treated group (Figure 4).

The GSH level was significantly \((p<0.001)\) in the liver and \((p<0.05)\) in renal tissue while the activity was found insignificantly \((p>0.05)\) increased in plasma and brain tissue of the control group (Figure 4). After treatment with the drug, these levels were increased along with significant increased their ratio in the plasma and tissues of treated group as compared to the cadmium exposed group (Tables 1 and 2).

Total thiol level was significantly \((p<0.001; p<0.001; p<0.01; p<0.001)\) lowered in plasma, brain, liver and renal tissue of the cadmium exposed group. Total thiol level was significantly elevated in plasma and tissues of the treated group after treatment with ceftriaxone plus sulbactam with VRP1034 for 21 days (Table 2). There were highly significant increases \((p<0.001)\) in malondialdehyde (MDA)

**Table 1. Effect of ceftriaxone plus sulbactam with VRP1034 on GSH, GSSG levels in cadmium exposed group after 21 days of treatment.**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Plasma</th>
<th>Brain</th>
<th>Liver</th>
<th>Kidney</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>GSH</td>
<td>GSGS</td>
<td>GSH</td>
<td>GSGS</td>
</tr>
<tr>
<td>Control group</td>
<td>3.96±0.96</td>
<td>0.81±0.17</td>
<td>4.89±0.88</td>
<td>0.55±0.11</td>
</tr>
<tr>
<td>Cadmium exposed</td>
<td>1.55±0.48***</td>
<td>1.03±0.04***</td>
<td>2.25±0.11***</td>
<td>0.89±0.09***</td>
</tr>
<tr>
<td>Ceftriaxone plus sulbactam with VRP1034 treated group</td>
<td>2.09±0.85ns</td>
<td>0.78±0.11ns</td>
<td>3.96±0.66***</td>
<td>0.64±0.10***</td>
</tr>
</tbody>
</table>

All data are Mean ± SD of each group. The GSH and GSGS levels were expressed in the plasma (mg/dL) whereas in the tissues (μmol/g tissue). Newman-Keuls test was performed for statistical significance between control group vs Cd exposed group and Cd exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group. Where ***p<0.001 (highly significant); **p<0.01 (significant); *p<0.05 (significant) and Ns p>0.05 (non significant).

**Table 2. Effect of ceftriaxone plus sulbactam with VRP1034 on redox state and total thiol level in cadmium exposed group after 21 days of treatment.**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Plasma</th>
<th>Brain</th>
<th>Liver</th>
<th>Kidney</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>GSH/GSGS</td>
<td>Total thiol</td>
<td>GSH/GSGS</td>
<td>Total thiol</td>
</tr>
<tr>
<td>Control group</td>
<td>4.88</td>
<td>4.33±0.98</td>
<td>8.89</td>
<td>121.4±10.85</td>
</tr>
<tr>
<td>Cadmium exposed</td>
<td>1.5</td>
<td>1.57±0.34***</td>
<td>2.52</td>
<td>98.7±8.17***</td>
</tr>
<tr>
<td>Ceftriaxone plus sulbactam with VRP1034 treated group</td>
<td>2.68</td>
<td>1.99±0.73ns</td>
<td>6.19</td>
<td>104.3±10.21</td>
</tr>
</tbody>
</table>

All data are Mean ± SD of eight animals of each group. The thiol level was expressed in the plasma (μmol/min/ml) whereas in the tissues (μmol/g tissue). Newman-Keuls test was performed for statistical significance between control group vs Cd exposed group and Cd exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group. Where ***p<0.001 (highly significant); **p<0.01 (significant); *p<0.05 (significant); Ns p>0.05 (non significant).
### Table 3. Effect of ceftriaxone plus sulbactam with VRP1034 on oxidative stress parameters in cadmium exposed group after 21 days of treatment.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Plasma</th>
<th>Brain</th>
<th>Liver</th>
<th>Kidney</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MDA</td>
<td>MPO</td>
<td>MDA</td>
<td>MPO</td>
</tr>
<tr>
<td>Control group</td>
<td>153.1±7.38</td>
<td>5.63±1.28</td>
<td>83.41±5.86</td>
<td>23.10±3.54</td>
</tr>
<tr>
<td>Cadmium exposed group</td>
<td>274.3±10.29</td>
<td>8.44±0.98</td>
<td>115.20±6.01</td>
<td>32.45±2.09</td>
</tr>
<tr>
<td>Ceftriaxone plus sulbactam with VRP1034 treated group</td>
<td>210.6±11.52</td>
<td>6.25±1.99</td>
<td>103.36±8.28</td>
<td>29.42±2.63</td>
</tr>
</tbody>
</table>

All data are Mean ± SD of each group. The MDA and MPO levels were expressed in the plasma (μmol/min/ml) whereas in the tissues (μmol/g tissue). Newman-Keuls test was performed for statistical significance between control group vs Cd exposed group and Cd exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group. Where ***p<0.001 (highly significant); **p<0.01 (significant); *p<0.05 (significant); Ns p>0.05 (non significant).

### Table 4. Effect of ceftriaxone plus sulbactam with VRP1034 on xanthine oxidase (XO) and glutathione s transferase (GST) in cadmium exposed group after 21 days of treatment.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Plasma (nmol/min/ml)</th>
<th>Liver (nmol/min/g tissue)</th>
<th>Kidney (nmol/min/g tissue)</th>
<th>Brain (nmol/min/g tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>135.4±8.56</td>
<td>14.33±1.52</td>
<td>44.10±2.65</td>
<td>25.12±1.87</td>
</tr>
<tr>
<td>Cadmium exposed group</td>
<td>296.3±10.22</td>
<td>18.96±1.10</td>
<td>87.33±6.02</td>
<td>51.05±2.64</td>
</tr>
<tr>
<td>Ceftriaxone plus sulbactam with VRP1034 group</td>
<td>168.7±14.31</td>
<td>13.74±0.55</td>
<td>71.82±4.49</td>
<td>37.0±2.09</td>
</tr>
</tbody>
</table>

All data are Mean ± SD of each group. The XO and GST levels were expressed in the plasma (μmole/min/ml) whereas in the tissues (μmol/g tissue). Newman-Keuls test was performed for statistical significance between control group vs Cd exposed group and Cd exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group. Where ***p<0.001 (highly significant); **p<0.01 (significant); *p<0.05 (significant); Ns p>0.05 (non significant).

### Table 5. Effect of ceftriaxone plus sulbactam with VRP1034 on hepatic and renal parameters in cadmium exposed group after 21 days of treatment.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Plasma</th>
<th>Liver</th>
<th>Kidney</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SGOT</td>
<td>SGPT</td>
<td>Creatinine</td>
</tr>
<tr>
<td>Control group</td>
<td>10.10±2.45</td>
<td>12.97±2.63</td>
<td>19.56±3.54</td>
</tr>
<tr>
<td>Cadmium exposed group</td>
<td>88.56±4.56</td>
<td>115.12±1.07</td>
<td>5.98±0.63</td>
</tr>
<tr>
<td>Ceftriaxone plus sulbactam with VRP1034 treated group</td>
<td>34.12±5.47</td>
<td>66.39±3.25</td>
<td>14.25±1.14</td>
</tr>
</tbody>
</table>

All data are Mean ± SD of each group. These parameters were expressed in the plasma (IU/L) whereas in the tissues (mmol/g tissue). Newman-Keuls test was performed for statistical significance between control group vs Cd exposed group and Cd exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group. Where ***p<0.001 (highly significant); **p<0.01 (significant); *p<0.05 (significant); Ns p>0.05 (non significant).

### Table 6. Effect of ceftriaxone plus sulbactam with VRP1034 on hematological and δ ALAD parameters in cadmium exposed group after 21 days of treatment.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Hb (g/dL)</th>
<th>RBC (10⁶/μL)</th>
<th>HCT %</th>
<th>WBC (10³/μL)</th>
<th>δ-ALAD in blood (nmol/min/ml erythrocyte)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>13.93±0.19</td>
<td>7.36±0.10</td>
<td>39.38±0.66</td>
<td>5.12±0.81</td>
<td>9.14±0.71</td>
</tr>
<tr>
<td>Cd-exposed</td>
<td>9.27±0.55</td>
<td>7.01±0.08</td>
<td>36.89±0.43</td>
<td>11.25±1.31</td>
<td>3.55±0.61</td>
</tr>
<tr>
<td>Cd+Ceftriaxone plus sulbactam with VRP1034 treated group</td>
<td>11.22±0.99</td>
<td>7.20±0.06</td>
<td>37.78±0.6</td>
<td>7.84±0.58</td>
<td>6.74±0.50</td>
</tr>
</tbody>
</table>

All data are Mean ± SD of each group. Newman-Keuls test was performed for statistical significance between control group vs Cd exposed group and Cd exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group. Where ***p<0.001 (highly significant); **p<0.01 (significant); *p<0.05 (significant); Ns p>0.05 (non significant).
and myeloperoxidase (MPO) levels in plasma and tissues of the CdCl₂ exposed group as compared to the control group after 21 days. After treatment with ceftriaxone plus sulbactam with VRP1034, the MDA and MPO parameters were significantly lowered \((p<0.001; p<0.05)\) in plasma, \((p<0.01; p>0.05)\) in brain, \((p<0.001)\) in liver and \((p<0.001; p>0.05)\) in renal tissue of the treated group as compared to the cadmium chloride group (Table 3). Xanthine oxidase (XO) and glutathione-S transferase (GST) activities were significantly \((p<0.001)\) altered in the plasma and tissues of the CdCl₂ induced group as compared with the control group. The GST activity was significantly increased \((p<0.001)\) along with significantly \((p<0.001)\) reduced XO activity in plasma and tissues of the treated group as compared to the CdCl₂ induced group after 21 days treatment. The GST and XO activities were found insignificant in renal and brain tissue in comparison to the cadmium exposed group (Table 4).

Hepatic parameters (SGOT, SGPT) were significantly increased in plasma and liver tissue while renal parameters (creatinine) was found to be increased in renal tissue of the cadmium exposed group as compared to the control group. These parameters were significantly lowered in plasma and tissues after treatment with ceftriaxone plus sulbactam with VRP1034 for 21 days (Table 5). Hematological parameters (Hb, RBC, WBC and HCT) were significantly altered in the cadmium exposed group as compared to the control group (Table 6). These parameters were improved after treatment with ceftriaxone plus sulbactam with VRP1034 for 21 days. The δ-ALAD enzyme activity was significantly inhibited in the blood of cadmium exposed group as compared to the control group. This activity was increased after treatment with ceftriaxone plus sulbactam with VRP1034 in the treated group as compared to the cadmium exposed group (Table 6). Cadmium concentration was found significantly \((p<0.001)\) increased in blood and all tissues of the CdCl₂ exposed group in comparison to the control group, while in brain tissue of the control group Cd concentration was not detected. The concentration of Cd was significantly \((p<0.001)\) minimized in blood and all tissues in the group treated by intravenous route with ceftriaxone plus sulbactam with VRP1034 after 21 days. (Table 7). Depletion of zinc and Fe levels was observed in liver, brain and renal tissues, while the zinc level was increased in blood of the cadmium exposed group as compared to the control group. These levels were significantly increased in plasma and all tissues of group treated with ceftriaxone plus sulbactam with VRP1034 (Table 8).

### Discussion

Cadmium from the environment enters into the body through the lungs and intestines. It is then transported into the blood and accumulates in the liver where it induces the synthesis of metallothionein (MT), a cytosolic protein to which cadmium binds. It is well known that heavy metals impair heme synthesis in the bone marrow and cause an increase of protoporphyrin-IX in erythrocytes. In the present study, there was significantly decreased δ-ALAD enzyme activity and hemoglobin levels along with increased cadmium concentration in blood and all tissues of the CdCl₂ induced group as compared to the control group. Due to inhibition of δ-ALAD, the Hb level was reduced in the cadmium exposed group, which confirming that Cd interference with the heme synthesis pathway leads to anemia. The heme metabolic pathway is highly susceptible to alterations induced by metal ions. Kannan and Flora (2004) reported that hemoglobin level and δ-aminolevulinic acid dehydratase activity were inhibited during heavy metal exposure in rats. Cd induced oxidative stress by increased lipid peroxidation level and inhibited antioxidant enzymes required to prevent the oxidative stress cadmium toxicity (Kelley et al., 1999). In our experiment, administration of CdCl₂ for 21 days via gastric gavage resulted in a significantly elevated malondialdehyde level (a marker of free radical), myeloperoxidase

<table>
<thead>
<tr>
<th>1337-6853 (print version)</th>
<th>1337-9569 (electronic version)</th>
</tr>
</thead>
</table>

Unauthenticated
Download Date | 6/22/17 8:40 AM
---

**Table 6.** Cadmium concentration was found significantly \((p<0.001)\) increased in blood and all tissues of the CdCl₂ exposed group in comparison to the control group, while in brain tissue of the control group Cd concentration was not detected. The concentration of Cd was significantly \((p<0.001)\) minimized in blood and all tissues in the group treated by intravenous route with ceftriaxone plus sulbactam with VRP1034 after 21 days. (Table 7). Depletion of zinc and Fe levels was observed in liver, brain and renal tissues, while the zinc level was increased in blood of the cadmium exposed group as compared to the control group. These levels were significantly increased in plasma and all tissues of group treated with ceftriaxone plus sulbactam with VRP1034 (Table 8).

**Figure 4.** Effect of Sulbactomax on glutathione peroxidase (GPx) activity in cadmium exposed rat. All data are Mean ± SD. GPx activity expressed in plasma (μmol/min/ml) whereas in liver, kidney and brain tissue (μmol/min/g tissue). Data are compared between control vs Cd exposed group and Cd exposed vs Cs+S with VRP1034 treated group. Where ***p<0.001 (highly significant); **p<0.01 (significant); *p<0.05 (significant) and **p>0.05.

**Figure 5.** Effect of ceftriaxone plus sulbactam with VR1M 034 on Total thiol level in cadmium exposed rat. All data are Mean ± SD of each group. The level expressed in plasma (μmol/ml) whereas in tissues (μmol/g tissue). Data are compared between control vs Cd exposed group and Cd exposed vs Cs+S with VRP1034 treated group. Where ***p<0.001 (highly significant); **p<0.01 (significant); *p<0.05 (significant) and **p>0.05.
levels and XO (free radical generating enzyme) along with significant reduction of endogenous antioxidant enzymes activities (SOD, CAT, GR, GPx, total thiol, GSH) in plasma and tissues of the cadmium chloride induced group as compared to the control group. The level of GSSG and the ratio GSH/GSSG was also significantly reduced in the cadmium exposed group as compared to the control group after administration of CdCl₂ for 21 days via gastric gavage. The depletion of GSH, increase in GSSG and the lowered GSH/GSSG ratio in blood, liver, brain and renal tissue were consistent with the accumulation of cadmium in these tissues. These alteration seem to be due to the generation of free radicals (Bray & Taylor, 1993). Our results were in accordance with various previous reports suggesting that cadmium metal can cause oxidative stress by interaction with -SH groups of the major intracellular defense glutathione. Other studies also reported increased lipid peroxidation in tissues of mice by a lowered tissue GSH level during cadmium intoxication. Cd exposure decreases the endogenous antioxidant enzyme (SOD, catalase, GR and GPx) activities along with increased lipid peroxidation and MPO levels in plasma, liver, brain and renal tissue as compared to the control group. Similarly, there was a significant reduction of total thiol level in plasma and all tissues of the cadmium exposed group as compared to the control group. Total thiol level decreases in the cadmium exposed group were due to the binding of thiol with cadmium metal. Various studies reported that alterations in endogenous antioxidant enzyme activities in different organisms following cadmium exposure depended on different periods of time, the amount of cadmium and the affected organs (Tandon et al, 2003; Jurczuk et al., 2006). Casalino et al., (2002 a,b) and Sen Gupta et al. (2004) reported similar results in experiments in rats. Asagba (2010) and Guilhermino et al. (1998) reported that cadmium exposure altered the hematological parameters in the cadmium exposed rat model. Thus in our study, there was a significant reduction in the hematological parameters (Hb, RBC and HCT%) in the cadmium exposed group. The hepatic and renal parameters were also significantly increased in the cadmium exposed group as compared with the control group. Renal impairment due to cadmium toxicity causes alterations in proximal tubules of kidney tissue. These findings also suggest that cadmium metal causes increased lipid peroxidation that imbalance the antioxidant defense system, which leads to organs damage and dysfunction. δ-ALAD activity decreased in blood along with significantly decreased Zn and Fe levels in blood and tissue of the cadmium exposed group as compared to the control group. The inhibition of δ-ALAD in the cadmium exposed group was due to interference with the heme synthesis pathway. The inhibition of micronutrient (Zinc, Fe) levels in the cadmium exposed group was due to cellular inhibitory action of these metals themselves.

After treatment with ceftriaxone plus sulbactam with VRP1034 for 21 days, these antioxidant enzyme activities, along with xanthine oxidase, lipid peroxidation, MPO levels, hepatic and renal parameters were significantly improved in plasma and tissues of the treated group as compared to the Cd exposed group. The GSH/GSSG ratio, δ-ALAD, cadmium concentration and micro nutrients levels were also improved in plasma and tissues of the treated group as compared to the Cd exposed group. The increased δ-ALAD, SOD, catalase, GR and GPx antioxidant enzyme activities and decreased lipid peroxidation, MPO and cadmium level in the blood and tissues indicate that ceftriaxone plus sulbactam with VRP1034 exerted significant protective effects against cadmium-induced biochemical alterations in the treated rats.

### Table 7. Effect of ceftriaxone plus sulbactam with VRP1034 on cadmium level in blood and tissues after 21 days of treatment.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Blood (µg/ml)</th>
<th>Liver (µg/g tissue)</th>
<th>Kidney (µg/g tissue)</th>
<th>Brain (µg/g tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>0.15±0.011</td>
<td>0.68±0.13</td>
<td>0.12±0.01</td>
<td>ND</td>
</tr>
<tr>
<td>Cd exposed group</td>
<td>11.79±2.4***</td>
<td>16.87±1.17***</td>
<td>13.49±2.21***</td>
<td>3.89±0.27</td>
</tr>
<tr>
<td>Ceftriaxone plus sulbactam with VRP1034 treated group</td>
<td>6.75±0.89***</td>
<td>10.11±0.83***</td>
<td>9.55±1.07***</td>
<td>0.62±0.12***</td>
</tr>
</tbody>
</table>

All data are Mean ± SD of each group. Newman-Keuls test was performed for statistical significance between control group vs Cd exposed group and Cd exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group. Where ***p<0.001 (highly significant); **p<0.01(significant); *p<0.05 (significant); Ns=p>0.05 (non significant).

### Table 8. Effect of ceftriaxone plus sulbactam with VRP1034 on Zinc and Fe levels in blood and tissues after 20 days of treatment.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Zinc (µg/ml)</th>
<th>Fe (µg/ml)</th>
<th>Liver (µg/g tissue)</th>
<th>Zinc (µg/g tissue)</th>
<th>Fe (µg/g tissue)</th>
<th>Kidney (µg/g tissue)</th>
<th>Zinc (µg/g tissue)</th>
<th>Fe (µg/g tissue)</th>
<th>Brain (µg/g tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>4.1±0.28</td>
<td>2.89±0.21</td>
<td>38.96±2.45</td>
<td>15.65±1.02</td>
<td>20.11±1.25</td>
<td>9.61±1.58</td>
<td>10.25±0.98</td>
<td>20.12</td>
<td></td>
</tr>
<tr>
<td>Cd exposed group</td>
<td>6.37±0.53***</td>
<td>0.33±0.01***</td>
<td>21.04±3.22***</td>
<td>8.87±1.56***</td>
<td>18.96±1.93***</td>
<td>3.67±0.59***</td>
<td>6.69±0.71***</td>
<td>6.78±1.15***</td>
<td></td>
</tr>
<tr>
<td>Ceftriaxone plus sulbactam with VRP1034 treated group</td>
<td>5.02±0.19***</td>
<td>0.72±0.01***</td>
<td>24.56±1.5*</td>
<td>10.23±2.10***</td>
<td>19.44±2.78***</td>
<td>5.03±0.97*</td>
<td>9.85±1.28***</td>
<td>13.87±2.31***</td>
<td></td>
</tr>
</tbody>
</table>

All data are Mean ± SD of each group. Newman-Keuls test was performed for statistical significance between control group vs Cd exposed group and Cd exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group. Where ***p<0.001 (highly significant); **p<0.01(significant); *p<0.05 (significant); Ns=p>0.05 (non significant).
antioxidant and chelating properties. Ceftriaxone and sulbactam individually interact with heavy and trans metals and form a complex which chelates out from the sulfhydryl group of antibiotics. But due to the presence of VRP1034 in ceftriaxone plus sulbactam, this combination showed synergistic effect that enhanced the free radical scavenging and chelating properties. Various studies reported that ceftriaxone and sulbactam individually showed free radical scavenging properties (Lapenna et al., 1995; Gunther et al., 1993). Our previous findings also showed that ceftriaxone plus sulbactam with VRP1034 was an effective drug for removal of arsenic intoxication in rats (Dwivedi et al., 2011). To our knowledge, there are no articles available on the combination of two antibiotics (beta lactam and beta lactamase inhibitor) exerting metal chelating properties. On the basis of the above results it is concluded that ceftriaxone plus sulbactam with VRP1034 is a protective and effective drug for removal of heavy metal from the body and plays a significant role in improving the endogenous antioxidant defense system along with reducing oxidative stress and protecting from hepatic and renal injury during cadmium toxicity.

Acknowledgments

The authors thank the Joint Managing Director of Venus Medicine Research Centre, Baddi, H.P., for providing the infrastructure to carry out this valuable experiment.

Conflict of interest: There are no conflicts of interest among the authors regarding the publication of this article.

REFERENCES


ISSN: 1337-6853 (print version) | 1337-9569 (electronic version)